Roche Diagnostics Corp.is bullish about the prospects of liquid biopsies both as a tool to remake cancer treatment monitoring and diagnostics, but also, in particular, to improve cancer trial clinical trials.
In an interview with The Gray Sheet, Walter Koch, a vice president and head of research of Roche's molecular diagnostics unit, says that replacing tissue biopsies with less-invasive liquid biopsies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?